The BMSF DCTCDP application will be a 2-step process, which includes:
1) Submission of a Letter of Intent (LOI), and
2) Upon review, selected candidates will be invited to submit a full Application.
Eligible candidates will reflect the National Science Foundation (NSF) definition of underrepresented populations in the US Biomedical, Clinical, Behavioral and Social Sciences Research Enterprise:
OR have a demonstrated commitment to increasing diverse patient participation in clinical trials.
Citizenship or immigration status
Eligible candidates will be US Citizens or Lawful Permanent Residents (LPRs) as defined by the US Department of Homeland Security. [NOTE: H-1B, J-1, & O-1 Visa holders are eligible; the Visa must be valid during the full 2-yr period]
Eligible candidates will hold the degree of MD, MD/PhD, DO or DO/PhD
Early Stage Investigator (ESI): As defined by NIH, a new investigator who has completed his or her terminal research degree or medical residency—whichever date is later—within the past 10 years and has not yet competed successfully for a substantial, competing NIH research grant. (Applicants with an RO1 or RO1 equivalent are ineligible.)
Application Process Opens:
Letter of Intent & Invited Full Application
Jan 4, 2021
LOI Submission Closes:
May 28, 2021
July 2, 2021
July 2 - Aug 31, 2021
Sep 1, 2021
First Cohort Begins:
Note: Dates are subject to change.
Copyright © 2020 Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program. All Rights Reserved.